贵州籍人群EHF疫苗接种后抗体应答及细胞因子变化  

Changes of cytokines and the immune response after EHF vaccine inoculation in Guizhou nationalities

作　　者：蔡静[1] 孙万邦[1] 罗军敏[1] 张忆雄[1] 宋明英[1] 

机构地区：[1]遵义医学院免疫学教研室,遵义563003

出　　处：《免疫学杂志》2005年第4期317-319,共3页Immunological Journal

基　　金：国家自然科学基金资助项目(30360099)

摘　　要：目的探讨贵州籍人群对EHF疫苗抗体应答能力和免疫后细胞因子的变化。方法对60名贵州健康自愿者进行EHF双价灭活疫苗全程接种,共3次(第07、、28天),接种前及末次接种后2周用间接免疫荧光法(IFA)检测血清抗EHF抗体水平,效价≥1∶640为高应答者;效价≤1∶80为低应答者,ELISA法检测高低应答组人群血清TNF-α、IFN-γ。结果60名EHF疫苗接种者均对EHF疫苗产生免疫应答,汉族46人中19人(41%)为高应答者,5人(10%)为低应答者;侗族10人中5人(50%)为高应答者,3人(30%)为低应答者;布依族4人中1人为高应答者,1人为低应答者,疫苗接种后TNF-αI、FN-γ均有升高。结论60名EHF疫苗接种者均对EHF疫苗产生免疫应答,其中汉族、侗族、布依族对EHF疫苗的抗体应答能力有所不同,同时诱导TNF-αI、FN-γ的分泌。Objective To study the immune response to EHF vaccine and the change of cytokines in Guizhou nationalities. Me-(thods A) total of 60 health volunteers from Guizhou province were subjected to a standard course of immunization with EHF defunct vaccine at day (0, 7,) and 28 successively. Two weeks after the last immunization, serum levels of anti-EHF antibody were detected by IFA. According to the titers, the individuals were divided into high-responders (titre≥1∶640) and low-responders (titre≤1∶80). The quantity of IFN-γ and TNF-α in high-responders and low-responders were assayed with ELISA. Results After immunization, all of the 60 subjects had specific immune response to EHF vaccine. For Han nationality, 41% (19/46) subjects were high-responders and 10% (5/46) were low-responders; for Dong nationality, 50% (5/10) subjects were high-responders and 30% (3/10) were low-responders; for Bu nationality, 25% (1/4) subjects were high-responders and 25% (1/4) were low-responders. The quantity of TNF-α and IFN-γ had raised after immunization with EHF vaccine in high-responds and low-responds(P > 0.05). Conclusion All of the 60 subjects raise the specific immune response and secrete TNF-α, as well as IFN-γ after immunization with EHF vaccine, but the immune responses to EHF vaccine in nationality of Han, Dong, and Bu are difference.

关 键 词：EHF疫苗 抗体 TNF-Α IFN-Γ 

分 类 号：R392[医药卫生—免疫学]